5-Year Update of the ECHELON-1 Study

A 10-year PFS simulation model based on the ECHELON-1 trial in Hodgkin lymphomaПодробнее

5-year follow-up of ECHELON-1: brentuximab plus AVD versus ABVD in Hodgkin lymphomaПодробнее

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphomaПодробнее

Phase III ECHELON-1 study: Updated results of brentuximab vedotin + chemotherapy for untreated cHLПодробнее

Five year update of ECHELON-1 for classical Hodgkin lymphomaПодробнее

Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trialПодробнее

5-Year Update of the ECHELON-1 StudyПодробнее